Zacks Investment Research upgraded shares of Evotec AG (NASDAQ:EVTCY) from a hold rating to a buy rating in a research report sent to investors on Friday morning. They currently have $43.00 price objective on the stock.

According to Zacks, “EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries “

A number of other equities analysts have also recently issued reports on the company. Berenberg Bank reiterated a buy rating on shares of Evotec AG in a report on Wednesday, May 10th. DZ Bank AG reiterated a sell rating on shares of Evotec AG in a report on Thursday, August 17th.

Evotec AG (NASDAQ:EVTCY) opened at 39.40 on Friday. The firm has a market capitalization of $2.88 billion and a PE ratio of 67.70. The company has a 50 day moving average price of $32.69 and a 200-day moving average price of $26.12. Evotec AG has a one year low of $9.79 and a one year high of $40.23.

Evotec AG (NASDAQ:EVTCY) last released its quarterly earnings data on Thursday, August 10th. The company reported $0.04 EPS for the quarter, missing the Zacks’ consensus estimate of $0.07 by $0.03. The company had revenue of $58.52 million for the quarter, compared to analyst estimates of $50.06 million.

COPYRIGHT VIOLATION WARNING: “Evotec AG (EVTCY) Rating Increased to Buy at Zacks Investment Research” was posted by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.watchlistnews.com/evotec-ag-evtcy-rating-increased-to-buy-at-zacks-investment-research/1542430.html.

About Evotec AG

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.

Get a free copy of the Zacks research report on Evotec AG (EVTCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with Analyst Ratings Network's FREE daily email newsletter.